GlassScriptPhysician profile
Alicia Van
NPI 1609938398
$4,096.55
in general payments reported to CMS, 2019-2025
13 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $65.86 · 2021: $476 · 2022: $716 · 2023: $596 · 2024: $633 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182 · Entertainment: $54.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.15 |
| Entertainment | $54.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,327.86 | 2022-2025 | Infuse, Biotrue One Day, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $956.76 | 2019-2021 | |
| Amgen INC. | $356.52 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $266.46 | 2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $256.84 | 2019-2025 | Acuvue |
| Abbvie INC. | $248.59 | 2022-2023 | Xen Glaucoma Treatment System |
| Allergan, INC. | $167.92 | 2020-2022 | |
| Glaukos Corporation | $155.35 | 2025 | Photrexa Viscous and Photrexa |
| Horizon Therapeutics Plc | $149.00 | 2023 | Tepezza |
| Alcon Vision LLC | $124.71 | 2025 | Rocklatan, Simbrinza, Rhopressa |
| Optos, INC. | $54.80 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Coopervision INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Van listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.